Synergistic interaction of cefotaxime and its metabolite desacetylcefotaxime demonstrated by drug-impregnated disks. 1989

D L Stevens, and R Bergstrom, and A Gibbons
Infectious Disease Section, Veterans Administration Medical Center, Boise, Idaho 82702.

Because no simple in vitro test for cefotaxime (CTX) and desacetylcefotaxime (dCTX) synergy exists, and, because no disk susceptibility data is available for dCTX, we investigated the potential of antibiotic impregnated disks as a test for positive in vitro interaction. Results of this study indicate that all strains of Staphylococcus aureus tested demonstrated additive interactions using disks that contained 30 micrograms of dCTX. In contrast, it was necessary to use much smaller concentrations of each cephalosporin to demonstrate additive effects against Gram-negative bacteria. Zones of inhibition were greater for disks containing the combination compared to either CTX or dCTX alone, among all the Gram-negative genera tested; however, these differences were statistically significant only for Klebsiella pneumoniae and Escherichia coli (P less than 0.05). These results demonstrate that disk susceptibility testing is reliable for the CTX metabolite, dCTX, and suggests that this technique using disks impregnated with CTX and dCTX singly and in combination is a simple method with which to evaluate positive antimicrobial interactions in the clinical laboratory.

UI MeSH Term Description Entries
D007711 Klebsiella pneumoniae Gram-negative, non-motile, capsulated, gas-producing rods found widely in nature and associated with urinary and respiratory infections in humans. Bacillus pneumoniae,Bacterium pneumoniae crouposae,Hyalococcus pneumoniae,Klebsiella pneumoniae aerogenes,Klebsiella rhinoscleromatis
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010403 Penicillin Resistance Nonsusceptibility of an organism to the action of penicillins. Penicillin Resistances,Resistance, Penicillin,Resistances, Penicillin
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004754 Enterobacter Gram-negative gas-producing rods found in feces of humans and other animals, sewage, soil, water, and dairy products.
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D006090 Gram-Negative Bacteria Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. Gram Negative Bacteria
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

D L Stevens, and R Bergstrom, and A Gibbons
February 1991, Journal of chemotherapy (Florence, Italy),
D L Stevens, and R Bergstrom, and A Gibbons
May 1988, The Japanese journal of antibiotics,
D L Stevens, and R Bergstrom, and A Gibbons
December 1988, Clinical pharmacy,
D L Stevens, and R Bergstrom, and A Gibbons
June 1988, Diagnostic microbiology and infectious disease,
D L Stevens, and R Bergstrom, and A Gibbons
July 1989, Xenobiotica; the fate of foreign compounds in biological systems,
D L Stevens, and R Bergstrom, and A Gibbons
January 1986, Drugs under experimental and clinical research,
D L Stevens, and R Bergstrom, and A Gibbons
January 1987, La Revue de medecine interne,
Copied contents to your clipboard!